Vis enkel innførsel

dc.contributor.authorAlam, Zufishan
dc.contributor.authorMohamed, Salma
dc.contributor.authorNauman, Javaid
dc.contributor.authorAl-Rifai, Rami H.
dc.contributor.authorAhmed, Luai A.
dc.contributor.authorElbarazi, Iffat
dc.date.accessioned2023-11-07T14:13:24Z
dc.date.available2023-11-07T14:13:24Z
dc.date.created2023-09-04T10:22:23Z
dc.date.issued2023
dc.identifier.citationHuman Vaccines & Immunotherapeutics. 2023, 19 (2), .en_US
dc.identifier.issn2164-5515
dc.identifier.urihttps://hdl.handle.net/11250/3101171
dc.description.abstractDespite widespread availability of vaccines against SARS-CoV-2 virus, the cause of Coronavirus Disease 2019 (COVID-19), its uptake in many Arab countries is relatively low. This literature review aimed to scope evidence on COVID-19 vaccine hesitancy (VH) in the Arab world. A total of 134 articles reporting prevalence of COVID-19 VH and associated factors, conducted in any of the 22 Arab League countries, were reviewed. COVID-19 VH prevalence ranged from 5.4% to 83.0%. Female gender, young age, low education level and lack of previous influenza vaccine uptake were most commonly reported to be associated with COVID-19 VH. The most-reported personal concerns contributing toward VH were related to the rapid development, safety and side effects of vaccine, as well as an overall lack of trust in government policies toward pandemic control and widespread conspiracy theories. Tailored interventions to enable the distribution of trusted information and enhance public acceptance of immunization are warranted.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleHesitancy toward vaccination against COVID-19: A scoping review of prevalence and associated factors in the Arab worlden_US
dc.title.alternativeHesitancy toward vaccination against COVID-19: A scoping review of prevalence and associated factors in the Arab worlden_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber0en_US
dc.source.volume19en_US
dc.source.journalHuman Vaccines & Immunotherapeuticsen_US
dc.source.issue2en_US
dc.identifier.doi10.1080/21645515.2023.2245720
dc.identifier.cristin2171998
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal